



Correspondence



COVID-19, A and Hypersensitivity Pneumonitis

Beuy Joob ¹ and Viroj Wiwanikit ^{2,3}

¹Sanitation 1 Medical Academic Center, Bangkok, Thailand

²Department of Community Medicine, Dr DY Patil, Pune, India

³Department of Tropical Medicine, Hainan Medical University, Haikou, China

OPEN ACCESS

Received: Apr 3, 2020

Accepted: Apr 7, 2020

Corresponding Author:

Beuy Joob, MD

Sanitation 1 Medical Academic Center,
Bangkok, Thailand.

Tel: (66) 24658292

Fax: (66) 24658292

E-mail: beuyjoob@hotmail.com

Copyright © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Beuy Joob

<https://orcid.org/0000-0002-5281-0369>

Viroj Wiwanikit

<https://orcid.org/0000-0003-1039-3728>

Conflict of Interest

No conflicts of interest.

Author Contributions

Investigation: BJ. Methodology: BJ. Project

administration: BJ. Supervision: VW.

Validation: VW. Writing – original draft: VW.

Writing – review & editing: BJ, VW

► See the article “COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis” in volume 52 on page 110.

Dear Editor,

We found that the article “COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis” is very interesting [1]. Song and Shin noted that “*Prophylactic and therapeutic low dose steroid oral tablets/inhalers at the earlier stage of COVID-19 and high dose steroid treatment according to the severity of the disease can play important roles in decreasing the fatality and pulmonary fibrosis*” [1]. We would like to share ideas from our country, the second country in the timeline of COVID-19 pandemic [2]. Here, the steroid has never been used for management of the patients. The general management is usually based on chloroquine and anti human immunodeficiency virus drugs. For the patients with mild symptom, the complete recovery can be seen in a short period. At present (3th March 2020), there are 1,978 COVID patients in Thailand. Of these cases, 7 had underlying asthma and on high dose steroid therapy. It is apparently that the patients still have poor clinical course despite the use of steroid. The role of steroid in COVID-19 should be further evaluated.

REFERENCES

1. Song YG, Shin HS. COVID-19, A clinical syndrome manifesting as hypersensitivity pneumonitis. Infect Chemother 2020;52:110-2.
[PUBMED](#) | [CROSSREF](#)
2. Yasri S, Wiwanikit V. Editorial: Wuhan coronavirus outbreak and imported case. Adv Trop Med Public Health Int 2019;9:1-2.